Orikine Presents Preclinical Data Demonstrating Sustained Myeloid Reprogramming and Disease Control with ORK1 in Inflammatory Bowel Disease at UEG Week 2026 - FirstWord Pharma

OHIO — New research shows that technology in the form of a wearable device could bring promise for future treatments against a form of aggressive breast cancer. The research from the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute involves a drug-free technology that uses low-intensity electric fields that was shown to reduce tumor growth and spread in preclinical models of triple-negative breast cancer.